WO2009124184A3 - Azabenzanthrones for the treatment of viral infections, cancer or restenosis - Google Patents

Azabenzanthrones for the treatment of viral infections, cancer or restenosis Download PDF

Info

Publication number
WO2009124184A3
WO2009124184A3 PCT/US2009/039294 US2009039294W WO2009124184A3 WO 2009124184 A3 WO2009124184 A3 WO 2009124184A3 US 2009039294 W US2009039294 W US 2009039294W WO 2009124184 A3 WO2009124184 A3 WO 2009124184A3
Authority
WO
WIPO (PCT)
Prior art keywords
restenosis
cancer
azabenzanthrones
treatment
viral infections
Prior art date
Application number
PCT/US2009/039294
Other languages
French (fr)
Other versions
WO2009124184A2 (en
Inventor
Robert H. Silverman
Babal Khant Jha
Original Assignee
The Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Cleveland Clinic Foundation filed Critical The Cleveland Clinic Foundation
Publication of WO2009124184A2 publication Critical patent/WO2009124184A2/en
Publication of WO2009124184A3 publication Critical patent/WO2009124184A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of activating RNase L in a subject in need thereof comprises administering to the subject an effective amount of a compound represented in Structural Formula (I) or a pharmaceutically acceptable salt thereof. The activation of RNase L treats a viral infection, cancer or restenosis.
PCT/US2009/039294 2008-04-04 2009-04-02 Methods of activating rnase l WO2009124184A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12300508P 2008-04-04 2008-04-04
US61/123,005 2008-04-04

Publications (2)

Publication Number Publication Date
WO2009124184A2 WO2009124184A2 (en) 2009-10-08
WO2009124184A3 true WO2009124184A3 (en) 2010-01-21

Family

ID=40849287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039294 WO2009124184A2 (en) 2008-04-04 2009-04-02 Methods of activating rnase l

Country Status (1)

Country Link
WO (1) WO2009124184A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110368386A (en) * 2019-08-23 2019-10-25 重庆化工职业学院 A kind of application of oxygen-containing endocyclic compound in the drug of preparation treatment malignant tumour
CN112807294B (en) * 2019-11-18 2023-09-05 武汉大学 Application of acyl thiourea compound in preparation of medicines for treating or preventing herpes simplex virus type I infection
US20230346829A1 (en) * 2020-05-11 2023-11-02 Revir, Inc. Compositions and methods for treating viral infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740581A (en) * 1987-02-24 1988-04-26 Eastman Kodak Company Condensation copolymers containing copolymerized isoquinoline derivative colorants and products therefrom
WO1998039287A1 (en) * 1997-03-05 1998-09-11 Trimeris, Inc. Benzanthrone compounds and antiviral uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740581A (en) * 1987-02-24 1988-04-26 Eastman Kodak Company Condensation copolymers containing copolymerized isoquinoline derivative colorants and products therefrom
WO1998039287A1 (en) * 1997-03-05 1998-09-11 Trimeris, Inc. Benzanthrone compounds and antiviral uses thereof

Also Published As

Publication number Publication date
WO2009124184A2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
HK1138184A1 (en) Combination medicaments for treating bacterial infections
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
HK1166788A1 (en)
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AP2012006227A0 (en) Derivatives of purine or deazapurine useful for the treatment of inter, alia viral, infections.
EA201270570A1 (en) COMBINED THERAPY OF CANCER DISEASES USING HSP90 INHIBITOR COMPOUNDS
SG178952A1 (en) Chemical compounds
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2010132777A3 (en) Treatment of urinary tract infections with antibacterial aminoglycoside compounds
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
MX2009003081A (en) Pyrrole derivatives useful for the treatment of cytokine-mediated diseases.
WO2012141796A3 (en) Prostate cancer therapy with hsp90 inhibitory compounds
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2010032011A8 (en) Anti-fungal therapy
WO2007106884A3 (en) Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MX2014003701A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease.
WO2008071961A8 (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
WO2007080401A8 (en) Triazoloanilinopyrimidine derivatives for use as antiviral agents
WO2009124184A3 (en) Azabenzanthrones for the treatment of viral infections, cancer or restenosis
MX348758B (en) Sanglifehrin derivatives and methods for their production.
WO2010025135A3 (en) Trimeprazine and ethopropazine derivatives for promoting bone growth

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09727886

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09727886

Country of ref document: EP

Kind code of ref document: A2